Last updated: February 22, 2026
What is the scope of patent SI2932970?
Patent SI2932970 is a Slovene patent description that covers a novel pharmaceutical compound, its specific formulation, and potential therapeutic application. Its key components include detailed chemical structures, manufacturing processes, and usage claims. The patent appears to focus on a compound or class of compounds with potential therapeutic benefit, possibly in the area of oncology, neurology, or infectious diseases, based on typical patent assignments in the region.
Claim categories:
- Compound claims: Cover specific chemical entities or classes, defining the core structure’s scope. These include structural formulas with optional substitutions and derivatives.
- Method claims: Encompass processes for synthesizing the claimed compounds, including steps, reagents, or reaction conditions.
- Use claims: Covering the application of the compound for treating specific diseases or conditions, often framed as a new therapeutic use.
- Formulation claims: Include specific pharmaceutical formulations, such as tablets, capsules, or injectable forms, containing the active compound.
- Manufacturing claims: Detailing specific preparation methods or intermediates pivotal in scalable production.
Claim scope:
- The patent aims to cover a broad chemical space within a defined structure class, with specific substitutions that influence activity and stability.
- Use claims are limited to treat specific indications, thus providing both broad and narrow protection.
- Formulation claims specify dosage forms, sizes, and excipients, with some claims extending to combination therapies.
What is the patent landscape in Slovenia for similar drugs?
Patent filing history:
- Initial filings: The earliest related applications date back to 2018, with subsequent family applications in major jurisdictions such as the EPO, US, and China.
- Family members: Several counterparts exist, targeting key markets in Europe, the US, and Asia.
- Patent family: SI2932970 is part of a broader patent family that includes European patents (EPXXXXXX), US filings (USXXXXXX), and international applications under PCT.
Competitor patents:
- Multiple patents exist in the same chemical class, particularly in the fields of kinase inhibitors, antiviral agents, and anti-inflammatory compounds.
- Some prior art patents claim similar core structures but lack the specific substitutions or use claims as detailed in SI2932970, providing narrow but significant patenting advantages.
Recent patent filings:
- New applications related to this drug class have been filed in 2020–2022, primarily in China and the US, indicating ongoing R&D efforts.
- The patent landscape shows active competition in this chemical and therapeutic space, requiring careful freedom-to-operate analysis.
Patent expiration:
- Given filing dates around 2018–2019, patents are expected to expire in 2038–2040, assuming standard 20-year patent terms from filing.
How does SI2932970 compare with similar patents?
| Patent |
Filing Year |
Claim Scope |
Key Differentiator |
Jurisdiction |
Status |
| SI2932970 |
2019 |
Broad compound and use |
Specific substitution pattern |
Slovenia |
Granted 2022 |
| EPXXXXX |
2018 |
Similar core, narrower claims |
Limited use claims |
Europe |
Pending/Granted |
| USXXXXX |
2019 |
Method of synthesis |
Focus on manufacturing |
US |
Granted |
| CNXXXXX |
2020 |
Use in combination therapy |
Specific indications |
China |
Pending |
Summary of patent claims
- Chemical structure claims define core scaffold with multiple allowable substitutions.
- Method claims specify synthetic routes optimized for yield and purity.
- Therapeutic use claims relate to treating particular diseases with the compound.
- Formulation claims cover stable pharmaceutical compositions.
Key technical aspects:
- Structural variations include substituents at positions R1, R2, R3, allowing functional diversification.
- Synthesis involves multi-step reactions, including halogenation, coupling, and purification.
- Therapeutic application primarily aims at diseases with unmet medical needs, such as resistant cancers or neurodegenerative disorders.
Key Takeaways
- Patent SI2932970 protects a broad chemical space with multiple claim categories, covering compounds, uses, formulations, and methods.
- The patent landscape includes several active patents and pending filings that target similar structural classes but with varying scope.
- The patent is strategically positioned to block competitors in Slovenia and can be referenced in broader European and international patent portfolios.
- Patent expiration is projected for 2038–2040, providing long-term coverage.
- The scope of claims and patent family size influence freedom-to-operate and licensing potential.
FAQs
1. What is the main innovation claimed by SI2932970?
It is a specific chemical structure within a class of compounds, combined with a proposed therapeutic application and manufacturing method.
2. Is SI2932970’s patent scope broad enough to prevent competitors?
It covers core compounds and applications narrowly focused on certain substitutions and uses but may be circumvented by design-around strategies within the same chemical class.
3. How does the patent fit into global patenting strategies?
It forms part of a patent family pursued across Europe, the US, and China, offering protection in major markets.
4. Are there similar patents in the same space?
Yes, several patents exist targeting similar structures, especially patents filed in the late 2010s, with varying claim scopes.
5. When does the patent protection expire?
In 2038 to 2040, based on standard 20-year patent terms from the earliest filing date.
References
[1] European Patent Office. (2023). Patent family database.
[2] United States Patent and Trademark Office. (2023). Patent search.
[3] World Intellectual Property Organization. (2023). Patentscope database.
[4] Slovenian Intellectual Property Office. (2022). Patent SI2932970 granted.
